The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets.


Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
07 2021
Historique:
received: 13 10 2020
accepted: 08 04 2021
pubmed: 29 4 2021
medline: 9 7 2021
entrez: 28 4 2021
Statut: ppublish

Résumé

SARS-CoV-2 entry requires sequential cleavage of the spike glycoprotein at the S1/S2 and the S2' cleavage sites to mediate membrane fusion. SARS-CoV-2 has a polybasic insertion (PRRAR) at the S1/S2 cleavage site that can be cleaved by furin. Using lentiviral pseudotypes and a cell-culture-adapted SARS-CoV-2 virus with an S1/S2 deletion, we show that the polybasic insertion endows SARS-CoV-2 with a selective advantage in lung cells and primary human airway epithelial cells, but impairs replication in Vero E6, a cell line used for passaging SARS-CoV-2. Using engineered spike variants and live virus competition assays and by measuring growth kinetics, we find that the selective advantage in lung and primary human airway epithelial cells depends on the expression of the cell surface protease TMPRSS2, which enables endosome-independent virus entry by a route that avoids antiviral IFITM proteins. SARS-CoV-2 virus lacking the S1/S2 furin cleavage site was shed to lower titres from infected ferrets and was not transmitted to cohoused sentinel animals, unlike wild-type virus. Analysis of 100,000 SARS-CoV-2 sequences derived from patients and 24 human postmortem tissues showed low frequencies of naturally occurring mutants that harbour deletions at the polybasic site. Taken together, our findings reveal that the furin cleavage site is an important determinant of SARS-CoV-2 transmission.

Identifiants

pubmed: 33907312
doi: 10.1038/s41564-021-00908-w
pii: 10.1038/s41564-021-00908-w
doi:

Substances chimiques

IFITM3 protein, human 0
Membrane Proteins 0
RNA-Binding Proteins 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Cathepsins EC 3.4.-
Serine Endopeptidases EC 3.4.21.-
TMPRSS2 protein, human EC 3.4.21.-
Furin EC 3.4.21.75

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

899-909

Subventions

Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/R013071/1
Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/R007292/1
Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/K002465/1
Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : DTP studentship
Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/M02542X/1
Organisme : RCUK | Biotechnology and Biological Sciences Research Council (BBSRC)
ID : BB/S008292/1
Organisme : Wellcome Trust
ID : 205100
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200187
Pays : United Kingdom
Organisme : Wellcome Trust (Wellcome)
ID : studentship
Organisme : Wellcome Trust (Wellcome)
ID : 216353/Z/19/Z
Organisme : RCUK | Medical Research Council (MRC)
ID : DTP studentship
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/R020566/1
Organisme : Imperial College London
ID : President's Scholarship
Organisme : Kings College London
ID : RE/18/2/34213
Organisme : Wellcome Trust
ID : 205100
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200187
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200187
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205100
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205100
Pays : United Kingdom
Organisme : FDA HHS
ID : HHSF223201510104C
Pays : United States

Références

Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
doi: 10.1038/s41586-020-2012-7 pubmed: 32015507 pmcid: 7095418
Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
doi: 10.1056/NEJMoa2001017 pubmed: 31978945 pmcid: 7092803
World Health Organisation. WHO Coronavirus Disease (COVID-19) Dashboard https://covid19.who.int/ (2021).
Matsuyama, S. et al. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 84, 12658–12664 (2010).
pubmed: 20926566 pmcid: 3004351
Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl Acad. Sci. USA 102, 11876–11881 (2005).
pubmed: 16081529 pmcid: 1188015
Millet, J. K. & Whittaker, G. R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl Acad. Sci. USA 111, 15214–15219 (2014).
pubmed: 25288733 pmcid: 4210292
Belouzard, S., Chu, V. C. & Whittaker, G. R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl Acad. Sci. USA 106, 5871–5876 (2009).
pubmed: 19321428 pmcid: 2660061
Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature https://doi.org/10.1038/s41586-020-2772-0 (2020).
Madu, I. G., Roth, S. L., Belouzard, S. & Whittaker, G. R. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J. Virol. 83, 7411–7421 (2009).
pubmed: 19439480 pmcid: 2708636
Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450–454 (2003).
pubmed: 14647384 pmcid: 7095016
Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc. Natl Acad. Sci. USA https://doi.org/10.1073/pnas.2003138117 (2020).
Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176, 104742 (2020).
pubmed: 32057769 pmcid: 7114094
Jaimes, J. A., Millet, J. K. & Whittaker, G. R. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site. iScience 23, 101212 (2020).
pubmed: 32512386 pmcid: 7255728
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 26, 450–452 (2020).
pubmed: 32284615
Boni, M. F. et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat. Microbiol. https://doi.org/10.1038/s41564-020-0771-4 (2020).
Le Coupanec, A. et al. Cleavage of a neuroinvasive human respiratory virus spike glycoprotein by proprotein convertases modulates neurovirulence and virus spread within the central nervous system. PLoS Pathog. 11, e1005261 (2015).
pubmed: 26545254 pmcid: 4636366
Park, J. E. et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc. Natl Acad. Sci. USA 113, 12262–12267 (2016).
pubmed: 27791014 pmcid: 5086990
Hoffmann, M., Kleine-Weber, H. & Pohlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell https://doi.org/10.1016/j.molcel.2020.04.022 (2020).
Bestle, D. et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance https://doi.org/10.26508/lsa.202000786 (2020).
Johnson, B. A. et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature https://doi.org/10.1038/s41586-021-03237-4 (2021).
Lau, S. Y. et al. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg. Microbes Infect. 9, 837–842 (2020).
pubmed: 32301390 pmcid: 7241555
Liu, Z. et al. Identification of common deletions in the spike protein of SARS-CoV-2. J. Virol. https://doi.org/10.1128/JVI.00790-20 (2020).
Ogando, N. S. et al. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol. https://doi.org/10.1099/jgv.0.001453 (2020).
Wong, Y. C. et al. Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients. Clin. Infect Dis. https://doi.org/10.1093/cid/ciaa953 (2020).
Klimstra, W. B. et al. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients. J. Gen. Virol. https://doi.org/10.1099/jgv.0.001481 (2020).
Davidson, A. D. et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. Genome Med. 12, 68 (2020).
pubmed: 32723359 pmcid: 7386171
Sasaki, M. et al. SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells. PLoS Pathog. 17, e1009233 (2021).
pubmed: 33476327 pmcid: 7853460
Zhu, Y. et al. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. Nat. Commun. 12, 961 (2021).
pubmed: 33574281 pmcid: 7878750
Xia, S. et al. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct. Target. Ther. 5, 92 (2020).
pubmed: 32532959 pmcid: 7289711
Shirato, K., Kawase, M. & Matsuyama, S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 87, 12552–12561 (2013).
pubmed: 24027332 pmcid: 3838146
Bertram, S. et al. TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J. Virol. 84, 10016–10025 (2010).
pubmed: 20631123 pmcid: 2937781
Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).
pubmed: 32221306 pmcid: 7100515
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).
pubmed: 32142651 pmcid: 7102627
Shulla, A. et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J. Virol. 85, 873–882 (2011).
pubmed: 21068237
Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001–7003 (2020).
pubmed: 32165541 pmcid: 7132130
Nao, N. et al. Consensus and variations in cell line specificity among human metapneumovirus strains. PLoS ONE 14, e0215822 (2019).
pubmed: 31013314 pmcid: 6478314
Bertram, S. et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J. Virol. 87, 6150–6160 (2013).
pubmed: 23536651 pmcid: 3648130
Zheng, M. et al. Bat SARS-lke WIV1 coronavirus uses the ACE2 of multiple animal species as receptor and evades IFITM3 restriction via TMPRSS2 activation of membrane fusion. Emerg. Microbes Infect. 9, 1567–1579 (2020).
pubmed: 32602823 pmcid: 7473123
Zhao, X. et al. LY6E restricts the entry of human coronaviruses, including the currently pandemic SARS-CoV-2. J. Virol. https://doi.org/10.1128/JVI.00562-20 (2020).
Huang, I. C. et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7, e1001258 (2011).
pubmed: 21253575 pmcid: 3017121
Lin, T. Y. et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep. 5, 895–908 (2013).
pubmed: 24268777 pmcid: 3898084
Kim, Y. I. et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe 27, 704–709 (2020).
pubmed: 32259477 pmcid: 7144857
Richard, M. et al. SARS-CoV-2 is transmitted via contact and via the air between ferrets. Nat. Commun. 11, 3496 (2020).
pubmed: 32641684 pmcid: 7343828
Belser, J. A. et al. Ferrets as models for influenza virus transmission studies and pandemic risk assessments. Emerg. Infect. Dis. 24, 965–971 (2018).
pubmed: 29774862 pmcid: 6004870
Enserink, M. Coronavirus rips through Dutch mink farms, triggering culls. Science 368, 1169 (2020).
pubmed: 32527808
Oude Munnink, B. B. et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science https://doi.org/10.1126/science.abe5901 (2020).
Hanley, B. et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe https://doi.org/10.1016/S2666-5247(20)30115-4 (2020).
Lemmin, T., Kalbermatter, D., Harder, D., Plattet, P. & Fotiadis, D. Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein. J. Struct. Biol. X 4, 100038 (2020).
pubmed: 33043289 pmcid: 7534663
Winstone, H. et al. The polybasic cleavage site in the SARS-CoV-2 spike modulates viral sensitivity to type I interferon and IFITM2. J. Virol. https://doi.org/10.1128/JVI.02422-20 (2021).
Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013 (2020).
pubmed: 33243994 pmcid: 7693302
Hoffmann, M. et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2575-3 (2020).
Ou, T. et al. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. PLoS Pathog. 17, e1009212 (2021).
pubmed: 33465165 pmcid: 7845965
Rambaut, A. et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. virological.org https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (2020).
Kärber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 162, 480–483 (1931).
Long, J., Wright, E., Molesti, E., Temperton, N. & Barclay, W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Res 4, 30 (2015).
pubmed: 26069727 pmcid: 4431382
McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).
pubmed: 32647131 pmcid: 7347890
Rebendenne, A. et al. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J. Virol. https://doi.org/10.1128/jvi.02415-20 (2021).
Edie, S. et al. Survey of human chromosome 21 gene expression effects on early development in Danio rerio. G3 (Bethesda) 8, 2215–2223 (2018).
Sumner, R. P. et al. Disrupting HIV-1 capsid formation causes cGAS sensing of viral DNA. EMBO J. https://doi.org/10.15252/embj.2019103958 (2020).
Goldhill, D. H. et al. Determining the mutation bias of favipiravir in influenza virus using next-generation sequencing. J. Virol. https://doi.org/10.1128/JVI.01217-18 (2019).
Goldhill, D. H. et al. The mechanism of resistance to favipiravir in influenza. Proc. Natl Acad. Sci. USA 115, 11613–11618 (2018).
pubmed: 30352857 pmcid: 6233120
Jabara, C. B., Jones, C. D., Roach, J., Anderson, J. A. & Swanstrom, R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl Acad. Sci. USA 108, 20166–20171 (2011).
pubmed: 22135472 pmcid: 3250168
Ma, D. et al. Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea. Eye (Lond.) 34, 1212–1219 (2020).
Xu, Q. F. et al. Ultraviolet a enhances cathepsin L expression and activity via JNK pathway in human dermal fibroblasts. Chin. Med. J. (Engl.) 129, 2853–2860 (2016).
Zhou, Z. et al. The cAMP-responsive element binding protein (CREB) transcription factor regulates furin expression during human trophoblast syncytialization. Placenta 35, 907–918 (2014).
pubmed: 25175744
Xu-yang, Z. et al. Interferon-induced transmembrane protein 3 inhibits Hantaan virus infection, and its single nucleotide polymorphism rs12252 influences the severity of hemorrhagic fever with renal syndrome. Front. Immunol. https://doi.org/10.3389/fimmu.2016.00535 (2017).
Li, H. et al. Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. PLoS Pathog. 14, e1006821 (2018).
pubmed: 29300777 pmcid: 5771632

Auteurs

Thomas P Peacock (TP)

Department of Infectious Diseases, Imperial College London, London, UK.

Daniel H Goldhill (DH)

Department of Infectious Diseases, Imperial College London, London, UK.

Jie Zhou (J)

Department of Infectious Diseases, Imperial College London, London, UK.

Laury Baillon (L)

Department of Infectious Diseases, Imperial College London, London, UK.

Rebecca Frise (R)

Department of Infectious Diseases, Imperial College London, London, UK.

Olivia C Swann (OC)

Department of Infectious Diseases, Imperial College London, London, UK.

Ruthiran Kugathasan (R)

Department of Infectious Diseases, Imperial College London, London, UK.

Rebecca Penn (R)

Department of Infectious Diseases, Imperial College London, London, UK.

Jonathan C Brown (JC)

Department of Infectious Diseases, Imperial College London, London, UK.

Raul Y Sanchez-David (RY)

Department of Infectious Diseases, Imperial College London, London, UK.

Luca Braga (L)

British Hearth Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, UK.

Maia Kavanagh Williamson (MK)

School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Jack A Hassard (JA)

Department of Infectious Diseases, Imperial College London, London, UK.

Ecco Staller (E)

Department of Infectious Diseases, Imperial College London, London, UK.

Brian Hanley (B)

Department of Cellular Pathology, Northwest London Pathology, Imperial College London NHS Trust, London, UK.

Michael Osborn (M)

Department of Cellular Pathology, Northwest London Pathology, Imperial College London NHS Trust, London, UK.

Mauro Giacca (M)

British Hearth Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, King's College London, London, UK.

Andrew D Davidson (AD)

School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol, UK.

David A Matthews (DA)

School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, Bristol, UK.

Wendy S Barclay (WS)

Department of Infectious Diseases, Imperial College London, London, UK. w.barclay@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH